Poor prognosis in non-villous splenic marginal zone cell lymphoma is associated with p53 mutations.
We have recently reported a series of 15 non-villous splenic marginal zone lymphoma patients, six of whom showed p53 mutations (40%). This molecular alteration did not correlate with any particular clinico-pathologic feature at diagnosis. After a median follow-up of 56 months, four cases evolved into aggressive fatal non-Hodgkin's lymphoma (NHL) and two had refractory progressive disease; interestingly, p53 mutations were demonstrated in five of these patients at diagnosis. As the patients with wild-type p53 presented responsive or indolent disease, this genetic alteration may be an early marker of aggressive transformation or refractoriness. p53 evaluation at diagnosis could be advisable in this particular subset of NHL.
Baldini
L
L
Laboratorio di Ematologia Sperimentale e Genetica Molecolare, Istituto di Scienze Mediche dell'Università, Ospedale Maggiore IRCCS, Milano, Italy.
Guffanti
A
A
Cro
L
L
Fracchiolla
N S
NS
Colombi
M
M
Motta
M
M
Maiolo
A T
AT
Neri
A
A
D000293:Adolescent; D000328:Adult; D000368:Aged; D002471:Cell Transformation, Neoplastic; D005500:Follow-Up Studies; D016158:Genes, p53 / Q000235:genetics*; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000235:genetics*; D008875:Middle Aged; D009154:Mutation; D011379:Prognosis; D013160:Splenic Neoplasms / Q000235:genetics*